Screening for FGFR3-TACC3 fusions and FGFR1 activating mutations should be performed in all patients with newly diagnosed IDH wild-type gliomas and all midline gliomas, respectively, as these patients are potentially eligible for clinical trials of targeted therapies at recurrence (Table 2). This evidence concerns the gene IDH2 and glioma.